[DOI] [PubMed] [Google Scholar] 156.PETROV A, PEREKHVATOVA N, SKULACHEV M, et al
The beneficial effect of tirzepatide on hsCRP, a biomarker of systemic inflammation, YKL-40, a proinflammatory cytokine, and ICAM-1, a biomarker of endothelial dysfunction, was already detectable at 4 weeks, consistent with the salutary effects of GIP and GLP-1 on inflammation and atherosclerosis in experimental models [84,85,86]
J., San, A
To validate the network pharmacology predictions and better understand protein-ligand interactions, the molecular docking technique was applied to predict the direct binding patterns and binding free energies between the compound and target proteins, and to evaluate the affinity between LC and key target proteins
Notably, no signal for ION was detected with tirzepatide, a dual GLP-1/GIP receptor agonist used for diabetes and obesity, and comparator drugs such as metformin and insulin also showed no significant associations